Pages Menu
Categories Menu


ARTIMIST SPRAY_white_940x300


Preventing disease progression to prevent death

Most malaria deaths occur in rural areas where healthcare facilities are more often than not several hours away, it is therefore vital to slow-down the disease progression while on-route to a hospital where parenteral artemisinin derivatives or quinine can be administered.

At present the pre-referral phase of the treatment is managed through the administration of artesunate rectal suppository (ARS), if other options are not available. However, ARS is not indicated if a child is suffering with diarrhoea.

ArTiMist™ was designed with a child in mind; a child living in a challenging environment where healthcare resources can be very scarce and time is of the essence.

ArTiMist™ is the world’s first sub-lingual spray for the treatment of P. falciparum severe paediatric malaria. The active pharmaceutical ingredient in ArTiMist™ is artemether which is a widely used anti­-malarial and is currently administered by infusion or orally in a tablet form.

ArTiMist™ is administered sub-lingually (under the tongue) and enters the bloodstream where the parasite lives, attacking at a far greater speed than conventional tablets and reducing the need for continued hospitalisation whilst presenting significant cost savings to governments and relief organisations.

ArTiMist™ is especially effective in the treatment of children and young infants who are experiencing malaria-related gastro-intestinal problems and cannot tolerate oral treatments.


  • Does not require medically trained personnel to administer
  • Not affected by GI complications
  • By passes the liver and the significant metabolism seen from the first pass effect.
  • Does not require a fatty diet for maximum effect
  • Rapidly absorbed
  • Negates risk of infection from needle injury
  • Can be administered in comatose patients
  • Does not require cold chain storage
  • Long shelf life

ArTiMist™ addresses a major unmet medical need in the paediatric treatment of severe malaria and uncomplicated malaria with GI complications. It also directly addresses the WHO requirement to provide a novel solution to minimise treatment delays to reduce morbidity.

ArTiMist™ in 2011 was identified by Thompson Reuters as one of the World’s 5 most promising drugs in Phase III clinical development. Its intrinsic characteristics (efficacy, user-and-patient friendly, hygienic and non-toxic) could make ArTiMist™ the pre-referral treatment of choice, as its initial administration could be done at community level by individuals that are not necessarily medically trained.

Product characteristics

ArTiMist™ is contained in a 10mL, Type 1 glass bottle fitted with a valve pump and a 100µL actuator constructed from pharmaceutical grade materials and are commercially available off-the-shelf.

ArTiMist™ contains 7.9mL of 60mg per mL artemether in mygliol base with a menthol flavour.

Each container contains sufficient solution for 50 actuations; each actuation contains 6mg of artemether. Artemether is stable for 48 months at 30C 75%RH (ICH 4)